News and Events | Spark Biomedical

July 29, 2021

Media Coverage

FinPay & Spark Biomedical Partnership

This is some text inside of a div block.

FinPay LLC, a recognized leader in pre-care payments and patient engagement, announced an agreement with Spark Biomedical, Inc., a Texas-based medical device company and developer of the first FDA-cleared, drug-free, personalized, wearable neurostimulation solution for opioid withdrawal — the Sparrow Therapy System.

May 26, 2021

Press Releases

Sierra Tucson Combats Opioid Withdrawal Using Groundbreaking Wearable Neurostimulation Therapy

This is some text inside of a div block.

First residential treatment center in the nation to offer The Sparrow™ Therapy System.

February 18, 2021

Media Coverage

Dallas-Based Spark Biomedical Gets FDA Clearance for its Drug‑Free Solution to Opioid Withdrawal

This is some text inside of a div block.

The medical device startup developed the Sparrow Therapy System, a wearable neurostimulation device that provides drug-free opioid withdrawal relief. What's next? Spark also has another device in clinical trials to help the youngest victims of addiction—babies.

February 3, 2021

Press Releases

Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System

This is some text inside of a div block.

The First FDA Cleared, Drug-Free, Personalized Solution for Opioid Withdrawal Relief Now Available For Patient Use

January 4, 2021

Press Releases

Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults

This is some text inside of a div block.

A new class of opioid withdrawal treatment emerges in The Sparrow Therapy System — the first clinically proven, drug-free, needle-free, wearable neurostimulation solution for opioid withdrawal relief

December 15, 2020

Press Releases

Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System

This is some text inside of a div block.

Breakthrough Designation Helps Advance the Therapy Targeting a Significant Unmet Need in the Treatment of Neonatal Opioid Withdrawal Syndrome

September 18, 2020

Awards

Transcutaneous Auricular Neurostimulation (tAN™) for Opioid Withdrawal Selected as a Top Abstract by American Society of Pain and Neuroscience

This is some text inside of a div block.

Spark Biomedical, Inc, CARMAhealth, and Recovery Unplugged jointly developed abstract places second in the American Society of Pain and Neuroscience (ASPN) 2020 Annual Conference. The abstract entitled, Interim Results from a Randomized, Double-Blind, Controlled Trial Examining Use of Transcutaneous Auricular Neurostimulation (tAN) to Improve Symptoms Associated with Opioid Withdrawal, outlines initial results from the first 20 patients in the clinical trial targeting participants with opioid use disorder.

August 28, 2020

Press Releases

Nine of the Foremost Pain Management Physicians Join the Spark Biomedical, Inc. Medical Advisory Board

This is some text inside of a div block.

Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal relief — announces the official formation of the company’s Medical Advisory Board on Pain Management.

August 4, 2020

Clinical Trials

Neurostimulation Clinical Trial Shows Promising Initial Results in Easing Opioid Withdrawal Symptoms in Newborns

This is some text inside of a div block.

While instances of Neonatal Opioid Withdrawal Syndrome (NOWS) are still on the rise, and the eyes of the nation remain focused on a pandemic, the Medical University of South Carolina (MUSC) and Spark Biomedical, Inc. are tackling opioid withdrawal in newborns — the most innocent victims of the still-looming opioid crisis. This groundbreaking clinical trial pairs Spark’s Transcutaneous Auricular Neurostimulation (tAN™) device for newborns — the Roo — with the pediatric neurostimulation expertise and facilities of MUSC to develop a safe and more effective withdrawal relief solution for NOWS.

January 24, 2020

Awards

Spark Biomedical takes “Best in Show” at 2020 NANS

This is some text inside of a div block.

The highlight of the 2020 NANS session was a competition among 12 new and emerging firms in the neuromodulation industry. Each entrepreneur was give 10 minutes to present and then field questions from the judges and the audience in an effort to win cash prizes and “Best in Show.”

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

News & Events

News

FinPay & Spark Biomedical Partnership

Sierra Tucson Combats Opioid Withdrawal Using Groundbreaking Wearable Neurostimulation Therapy

Dallas-Based Spark Biomedical Gets FDA Clearance for its Drug‑Free Solution to Opioid Withdrawal

Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System

Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults

Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System

Transcutaneous Auricular Neurostimulation (tAN™) for Opioid Withdrawal Selected as a Top Abstract by American Society of Pain and Neuroscience

Nine of the Foremost Pain Management Physicians Join the Spark Biomedical, Inc. Medical Advisory Board

Neurostimulation Clinical Trial Shows Promising Initial Results in Easing Opioid Withdrawal Symptoms in Newborns

Spark Biomedical takes “Best in Show” at 2020 NANS

Media Inquiries